Literature DB >> 18767813

ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.

Kyriakos E Kypreos1.   

Abstract

In this study, the ability of the lipid transporter ABCA1 and apolipoprotein CIII (apoCIII) to promote the de novo biogenesis of apoCIII-containing HDL in vivo and the role of this HDL in apoCIII-induced hypertriglyceridemia were investigated, using adenovirus-mediated gene transfer in apoE (-/-) x apoA-I (-/-) mice or ABCA1 (-/-) mice. Injection of apoE (-/-) x apoA-I (-/-) mice with 8 x 10 (8) pfu of an adenovirus expressing the wild-type human apoCIII (AdGFP-CIII g) generated HDL-like particles and triggered only a modest increase in plasma cholesterol and triglyceride levels of these mice, 3-5 days postinfection. Plasma human apoCIII was distributed among HDL, VLDL/IDL, and LDL in these mice. In contrast, ABCA1 (-/-) mice treated similarly failed to form HDL particles and developed severe hypertriglyceridemia which could be alleviated by coinfection with an adenovirus expressing human LpL, while their plasma cholesterol levels remained unchanged 3-5 days postinfection with AdGFP-CIII g. Human apoCIII in these mice accumulated exclusively on VLDL. Control experiments confirmed that the differences between apoE (-/-) x apoA-I (-/-) and ABCA1 (-/-) mice expressing human apoCIII were not due to differences in apoCIII expression. Overall, these data show that ABCA1 and human apoCIII promote the formation of apoCIII-containing HDL-like particles that are distinct from classical apoE- or apoA-I-containing HDL. Formation of apoCIII-containing HDL prevents excess accumulation of plasma apoCIII on VLDL and allows for the efficient lipolysis of VLDL triglycerides by LpL. Furthermore, the data establish that ABCA1 and apoCIII-containing HDL play key roles in the prevention of apoCIII-induced hypertriglyceridemia in mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18767813     DOI: 10.1021/bi801249c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Identification of potential serum biomarkers for Wilms tumor after excluding confounding effects of common systemic inflammatory factors.

Authors:  Jiaxiang Wang; Lei Wang; Da Zhang; Yuxia Fan; Zhankui Jia; Pan Qin; Jiekai Yu; Shu Zheng; Fuquan Yang
Journal:  Mol Biol Rep       Date:  2011-12-08       Impact factor: 2.316

2.  Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry.

Authors:  Matthew T Mazur; Helene L Cardasis; Daniel S Spellman; Andy Liaw; Nathan A Yates; Ronald C Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-13       Impact factor: 11.205

3.  Adrenoceptor-related decrease in serum triglycerides is independent of PPARα activation.

Authors:  Maria Konstandi; Kyriakos E Kypreos; Tsutomu Matsubara; Eva Xepapadaki; Yatrik M Shah; Kristopher Krausz; Christina E Andriopoulou; Aristeidis Kofinas; Frank J Gonzalez
Journal:  FEBS J       Date:  2019-06-28       Impact factor: 5.542

4.  ABCA1 gene variants regulate postprandial lipid metabolism in healthy men.

Authors:  Javier Delgado-Lista; Pablo Perez-Martinez; Francisco Perez-Jimenez; Antonio Garcia-Rios; Francisco Fuentes; Carmen Marin; Purificación Gómez-Luna; Antonio Camargo; Laurence D Parnell; Jose Maria Ordovas; Jose Lopez-Miranda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-25       Impact factor: 8.311

Review 5.  High-density lipoprotein (HDL) metabolism and bone mass.

Authors:  Nicholaos I Papachristou; Harry C Blair; Kyriakos E Kypreos; Dionysios J Papachristou
Journal:  J Endocrinol       Date:  2017-03-17       Impact factor: 4.286

6.  Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism.

Authors:  Soonkyu Chung; Jenelle M Timmins; Myngan Duong; Chiara Degirolamo; Shunxing Rong; Janet K Sawyer; Roshni R Singaraja; Michael R Hayden; Nobuyo Maeda; Lawrence L Rudel; Gregory S Shelness; John S Parks
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

7.  Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity.

Authors:  Evangelia Zvintzou; Marie Lhomme; Stella Chasapi; Serafoula Filou; Vassilis Theodoropoulos; Eva Xapapadaki; Anatol Kontush; George Spyroulias; Constantinos C Tellis; Alexandros D Tselepis; Caterina Constantinou; Kyriakos E Kypreos
Journal:  J Lipid Res       Date:  2017-07-12       Impact factor: 5.922

Review 8.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

9.  Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice.

Authors:  Eleni A Karavia; Dionysios J Papachristou; Kassiani Liopeta; Irene-Eva Triantaphyllidou; Odyssefs Dimitrakopoulos; Kyriakos E Kypreos
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

10.  LXR Agonism Upregulates the Macrophage ABCA1/Syntrophin Protein Complex That Can Bind ApoA-I and Stabilized ABCA1 Protein, but Complex Loss Does Not Inhibit Lipid Efflux.

Authors:  Norimasa Tamehiro; Min Hi Park; Victoria Hawxhurst; Kamalpreet Nagpal; Marv E Adams; Vassilis I Zannis; Douglas T Golenbock; Michael L Fitzgerald
Journal:  Biochemistry       Date:  2015-11-09       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.